

































The	objective	of	 the	 research	was	 to	 study	 the	pathogenetic	 role	of	 the	
levels	 of	 endothelin-1	 (ET-1),	 tumor	 necrosis	 factor-alpha	 (TNF-alpha)	 and	 C-
reactive	 protein	 (CRP)	 in	 the	 development	 of	 endothelial	 dysfunction	 (ED)	 in	
patients	with	preserved	and	lost	renal	function.	
Materials	and	methods.	The	study	involved	86	patients:	Group	I	included	
42	patients	with	arterial	hypertension	and	chronic	heart	 failure	 (CHF)	 IIA	FC	 ІІІ;	
Group	 II	consisted	of	44	patients	with	terminal	chronic	kidney	disease	 (stage	V	
CKD)	 with	 concomitant	 CHF	 IIA	 FC	 ІІІ	 who	 were	 on	 treatment	 by	 outpatient	
program	hemodialysis	(HD).	
Results.	 In	 patients	 of	 Group	 II	 the	 levels	 of	 ET-1	 and	 inflammatory	
markers	 were	 significantly	 higher	 than	 those	 in	 the	 comparison	 and	 control	
groups	(p<0.001	and	p<0.001).	In	patients	of	Group	I	there	was	a	direct	moderate	
correlation	between	TNF-alpha	and	ET-1	 (r=0.48;	p<0.05)	and	between	CRP	and	
ET-1	 (r=0.56;	p<0.05).	 In	Group	 II,	the	relation	between	TNF-alpha	and	ET-1	was	
significantly	stronger	(r=0.58;	p<0.05);	between	the	levels	of	CRP	and	ET-1	it	was	



















rate	 of	 increase	 in	 incidence.	Nowadays,	 the	prevalence	 of	 this	 syndrome	 constitutes	 1-9%,	 the	
incidence	of	CHF	 increases	with	age	and	reaches	10-28%	after	the	age	of	65	 [2,	8].	The	prevalence	
of	CHF	is	much	higher	in	a	population	of	patients	with	terminal	chronic	kidney	disease	(CKD)	who	
are	 on	 hemodialysis	 (HD).	 Thus,	 CHF	 is	 diagnosed	 in	 almost	 one	 third	 of	 patients	 on	 HD	 [10].	
Endothelium	of	blood	 vessels	 intima	 is	 important	 in	 the	pathogenesis	of	CHF	development	 and	
progression.	 It	performs	barrier,	secretory,	homeostatic	 functions	and	plays	an	 important	role	 in	
the	processes	of	inflammation	and	remodeling	of	the	cardiovascular	system.	Endothelial	cells	are	
sensitive	 to	various	damaging	 factors	such	as	homeostasis	disorders,	 increased	concentration	of	
free	 radicals,	 cholesterol	 and	 inflammatory	mediators	under	 the	 influence	of	which	 endothelial	
dysfunction	 (ED)	 may	 develop	 being	 caused	 by	 an	 imbalance	 between	 substances	 providing	
vascular	tone	and	homeostasis	of	endothelium	processes	[4,	5,	13].	Under	physiological	conditions,	
the	secretion	of	vasoconstrictors	(angiotensin	II,	endothelin-1,	free	radicals,	thromboxane	A2)	and	
vasodilators	 (nitric	oxide,	hyperpolarizing	 relaxing	 factor,	prostacyclin	 I2)	 is	balanced.	However,	




damaging	 factors	 leads	 to	 a	 gradual	 deterioration	 and	 distortion	 of	 vasodilation	 compensatory	
mechanisms.	Thus,	 endothelium	 launches	mechanisms	 of	 vasoconstriction	 and	proliferation	 in	
response	 to	a	normal	 stimulus	 [1,	4,	5,	13].	Among	 the	endothelium-dependent	vasoconstrictors	
endothelin-1	(ET-1)	draws	the	attention	of	various	scientists	[1,	3,	6,	7,	11].	The	main	properties	of	
ET-1	 are	 its	 ability	 to	 affect	not	only	 the	 vascular	 tone	 causing	 vasoconstriction	 stable,	but	 also	
myocardial	 contractile	 function,	 the	 value	 of	 preload	 and	 afterload,	 platelet	 aggregation	 and	 to	
stimulate	the	development	of	myocardial	hypertrophy.	ED	is	a	characteristic	feature	accompanying	
CHF.	Many	studies	have	found	that	 increased	 levels	of	CRP	and	TNF-alpha	 in	blood	serum	are	an	
independent	predictor	of	CHF	progression	 [1,13,14].	However,	 the	 impact	of	 these	 inflammatory	
mediators	on	ED	severity	and	CHF	development	in	patients	requiring	replacement	therapy	is	poorly	
studied.		
The	objective	of	 the	 research	was	 to	determine	 the	pathogenetic	 role	of	ET-1,	TNF-alpha	





The	 study	 involved	 86	 patients:	Group	 I	 included	 42	patients	with	AH	 and	CHF	 IIA	 FC	 ІІІ	
(NYHA)	who	underwent	hospital	treatment	in	the	therapeutic	department	of	the	University	Clinic	







HD	was	performed	 to	patients	according	 to	 the	standard	program	 (3	 times	a	week	 for	4-5	











blood	 pressure	 (ABP)	 were	 determined	 in	 all	 patients	 by	 means	 of	 24-hour	 blood	 pressure	
monitoring.	 The	 clinical	 condition	 of	 the	 patient	 was	 assessed	 by	 total	 points	 according	 to	 the	
rating	 scale	 of	 clinical	 state	 (Yu.V.	Marieiev,	 2000)	 and	 6-minute	walking	 test	was	 conducted	 in	
order	to	clarify	the	functional	class	of	CHF	(according	to	NYHA	criteria).		CRP	level	was	determined	









of	 normal	 distribution,	 mean	 values	 (M)	 and	 mean	 error	 of	 arithmetical	 average	 (m)	 as	 well	 as	
standard	deviation	(SD)	were	estimated.	Student’s	t-test	was	used	to	compare	the	average	values	of	
two	independent	samples.	Median	and	interquartile	range	(25%	and	75%)	were	used	in	case	of	non-
compliance	of	 the	normal	distribution	 law	 for	description	of	 the	 features.	Nonparametric	Mann–






















Sex	(M/W)	 11/9	 23/19	 26/18	
Age,	years	 37.8±4.37	 54.6±5.47	 49.1±6.12	
AH	duration,	years	 -	 7.8±2.42	 6.7±0.87	
HD	treatment,	years	 -	 -	 3.58±1.32	
Hemoglobin,	GM/DL	 127.3±5.13	 112.4±4.16*	 96.4±3.07***̂ ˆ	
Erythrocytes,	10¹²/l	 4.68±0.34	 3.89±0.09	 3.41±0.64*	
Leukocytes,	10⁹/l	 5.1±0.47	 7.2±0.13	 7.6±0.15	
Erythrocyte	sedimentation	
rate,	mm/h	






Total	protein,	g/l	 73.1±3.84	 63.3±3.56*	 58.4±2.47**	
Albumins,	g/l	 52.2±3.21	 44.2±1.57*	 39.3±1.65**	
Total	cholesterol,	mmol/L	 4.17±1.11	 5.7±0.97	 6.3±1.12	
Urea,	mmol/L	 6.3±0.19	 7.1±0.24*	 14.3±1.15***̂ ˆˆ	
Urea	after		dialysis	 -	 -	 7.8±0.23*	
Creatinine,	mcmol/l	 74.8±3.53	 103.1±5.3	 792.2±40.4***̂ ˆˆ	
Creatinine	after		dialysis	 -	 -	 178.2±8.41***̂ ˆˆ	











of	 nitrogen	 metabolism	 were	 within	 normal	 range	 in	 patients	 of	 Group	 I	 whereas	 a	 significant	
increase	 in	 these	 data	 was	 observed	 in	 the	 group	 of	 dialysis	 patients	 even	 after	 adequate	 HD	
session	(р<0.001).	
In	 order	 to	 define	 vascular	 endothelium	 functions	 we	 studied	 the	 levels	 of	 ET-1.	 Many	
scientists	consider	 its	 increased	concentration	 to	be	associated	with	ED	 [7,	11].	The	 levels	of	CRP	
and	TNF-alpha	were	determined	 in	 all	patients	 of	Group	 I	 and	Group	 II	 (Table	 2).	The	 obtained	
results	 implied	 that	 the	 levels	 of	 ET-1	 and	 inflammatory	 markers	 were	 significantly	 higher	 in	
patients	of	Group	II	in	comparison	with	the	control	group	and	the	comparison	group	(p<0.001	and	















TNF-alpha,	pg/ml	 23.6±3.62	 63.2±12.29***	 103.5±25.61***̂ ˆˆ	
ET-1,	pg/ml	 5.3±0.32	 9.7±1.37**	 12.01±1.36***̂ ˆˆ	













Box & Whisker Plot
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Box & Whisker Plot
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Note:1 - Group I (AH with CHF)


























Recent	 studies	have	 found	a	 relation	between	 the	 level	of	TNF-alpha	and	CHF	 stage,	but	
such	 studies	 usually	 do	 not	 include	 patients	 who	 require	 replacement	 therapy	 [4].	 However,	
analyzing	the	data	obtained	in	our	research,	the	levels	of	these	inflammatory	markers	in	patients	










CRP Group I:  = -14.78+ .40059 * TNF-α Group I
Correlation: r = ,52413
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Increase	 in	 CRP	 and	 TNF-alpha	 is	 well	 known	 to	 be	 an	 independent	 predictor	 of	
cardiovascular	 events	 [4].	 Correlation	 analysis	 between	 these	 markers	 and	 ET-1	 level	 was	
performed	to	study	the	value	of	these	indices	in	the	development	of	ED	(Fig.	6	–	Fig	9).	




Established	 correlation	 between	 the	 level	 of	 TNF-alpha	 and	 ET-1	 in	 both	 study	 groups	
indicates	 that	 the	 simultaneous	 increase	 in	 these	 markers	 is	 a	 significant	 predictor	 of	 ED	 and	
cardiovascular	complications	in	patients	with	CHF	regardless	of	renal	function.	Since	ET-1	causes	
endothelium-dependent	vasoconstriction,	vessel	constriction	provokes	the	synthesis	of	TNF-alpha	
which	 affects	 the	 increase	 of	 ET-1indirectly	 through	 CRP.	 Thus,	 a	 “vicious	circle”	of	pathogenic	
changes	is	formed	leading	to	a	disease	progression.	At	the	same	time,	though	increase	in	CRP	level	








CRP Group ІI:  = -20.91+ .41085* TNF-α Group IІ
Correlation: r = ,64965
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CRP Group I:  = -24.07+ 3.5419 * ET-1 Group IІ
Correlation: r = ,55974
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CRP Group II:  = -30.52+ 4.5446 * ET-1 Group IІ
Correlation: r = ,37214
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TNF Group I:  = 20.226+ 4.3281 * ET-1 Group I
Correlation: r = ,48414
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TNF Group II:  = -26.76+ 10.963 * ET Group II
Correlation: r = ,57802
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